Aim
To analyze the short-term effectiveness and safety of TCZ in patients with JIA refractory to anti-TNF agents.
Methods
All patients who received TCZ due to refractory disease were included. All patients had exhibited anti-TNF primary or secondary failure. Data were retrieved from the Rheumatology Section data base. TCZ was administered intravenously at a dose of 8 mg/kg for patients > 30 Kg, 12 mg/Kg for patients < 30 Kg every 2 weeks. Efficacy endpoints included improvement (ACR Pedi30), disappearance of systemic symptoms, and reduction in corticosteroid dose.
Results
9 patients with JIA (7 systemic, 2 poliarticular, 7 F, 2 M) were included. Median age at study entry was 10 years, disease duration 6 years. They received TCZ for 3 to 9 months. Patients had been refractory to etanercept (9), adalimumab (7) 
Conclusions
Tocilizumab seems to be effective and safe with a rapid onset of action in children with anti-TNF refractory JIA.
